Apadamtase alfa
- Generic Name
- Apadamtase alfa
- Drug Type
- Biotech
- CAS Number
- 2086325-24-6
- Unique Ingredient Identifier
- U5SFU33XUX
- Background
Apadamtase alfa is under investigation in clinical trial NCT03922308 (Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)).
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT06441578
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan
Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Takeda
- Registration Number
- NCT05770219
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT05714969
- Locations
- 🇺🇸
University of Florida Shands, Gainesville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 77
- Registration Number
- NCT04683003
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Shire
- Target Recruit Count
- 19
- Registration Number
- NCT03997760
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸University of Tennessee -- Memphis, Memphis, Tennessee, United States
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Shire
- Target Recruit Count
- 28
- Registration Number
- NCT03922308
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇨🇦London Health Sciences Centre (LHSC) - University Hospital, London, Ontario, Canada
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Baxalta now part of Shire
- Target Recruit Count
- 52
- Registration Number
- NCT03393975
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Alliance for Childhood Diseases, Cure 4 the Kids Foundation, Las Vegas, Nevada, United States
Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
- Conditions
- Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Baxalta now part of Shire
- Target Recruit Count
- 16
- Registration Number
- NCT02216084
- Locations
- 🇨ðŸ‡
Inselspital - Universitaetsspital Bern, Bern, Switzerland
🇦🇹General Hospital Vienna (Allgemeines Krankenhaus der Stadt Wien), Vienna, Austria
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.